SOUTH SAN FRANCISCO, Calif., April 22, 2015 /PRNewswire/ -- MiNDERA Corp., a leader in the development of non-invasive diagnostic tests for dermatology, announced today the initiation of a research collaboration with an undisclosed partner. MiNDERA will utilize its proprietary micro-needle device technology to develop and test devices capable of extracting specific skin biomarkers designated by its partner. Under the terms of the agreement, MiNDERA is eligible to receive upfront and milestone payments upon achievement of defined development milestones.
"Since its founding, our company has experienced continued interest from major pharmaceutical and skin care companies," said Philippe Nore, MiNDERA's CEO and co-founder. "This first collaboration with a global market leader known for the quality of its research and innovation is a great validation and milestone for our company. It shows that large multinational companies believe that our technology has the potential to revolutionize the way skin conditions are studied, diagnosed and treated, and skin health is maintained. We are looking forward to advancing our technology with this new partner and are excited about the first phase of a long-term and fruitful partnership."
About MiNDERA: At the core of MiNDERA's products is a proprietary micro-needle device that enables pain free, minimally invasive and targeted extraction of biomarkers from the skin, without requiring a skin biopsy. These biomarkers are then eluted and analyzed by molecular techniques including PCR and next-generation sequencing to deliver a molecular profile of the sampled region. MiNDERA is pursuing research applications (whole transcriptome and skin microbiome extraction) as well as diagnostic applications for skin cancer and other skin diseases. Find out more at http://www.minderadx.com.
SOURCE MiNDERA Corporation